Nanoparticle‐based immune checkpoint inhibitor therapy, including PD‐1 or PD‐L1 blockers, increases the local concentration of immune checkpoint inhibitors while reduces the side effects in anti‐tumor therapies.52 Here, CD274 is linked to neoplasm.